Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a BetZacks Investment Research • 11/20/24
Corcept (CORT) is on the Move, Here's Why the Trend Could be SustainableZacks Investment Research • 11/20/24
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and TheravanceZacks Investment Research • 11/11/24
Corcept Therapeutics Incorporated (CORT) Soars to 52-Week High, Time to Cash Out?Zacks Investment Research • 11/05/24
Wall Street Analysts Believe Corcept (CORT) Could Rally 56.66%: Here's is How to TradeZacks Investment Research • 11/04/24
Earnings Estimates Moving Higher for Corcept (CORT): Time to Buy?Zacks Investment Research • 11/01/24
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue ViewZacks Investment Research • 10/31/24
Corcept Therapeutics (CORT) Tops Q3 Earnings and Revenue EstimatesZacks Investment Research • 10/30/24
Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing's Syndrome and Provides Corporate UpdateBusiness Wire • 10/30/24
Strength Seen in Corcept (CORT): Can Its 5.5% Jump Turn into More Strength?Zacks Investment Research • 10/21/24
Wall Street Analysts See a 43.01% Upside in Corcept (CORT): Can the Stock Really Move This High?Zacks Investment Research • 10/17/24
Corcept (CORT) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 10/17/24